We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+1.24%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$2.93B
AUM Growth
-$191M
Cap. Flow
-$51.4M
Cap. Flow %
-1.75%
Top 10 Hldgs %
43.92%
Holding
115
New
17
Increased
19
Reduced
24
Closed
19

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$145M
2
IMTX icon
Immatics
IMTX
+$43.5M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$38.6M
4
KO icon
Coca-Cola
KO
+$35.8M
5
CZR icon
Caesars Entertainment
CZR
+$30.6M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$78.3M
2
ACLX
Arcellx
ACLX
+$57.6M
3
RPRX icon
Royalty Pharma
RPRX
+$52.8M
4
T icon
AT&T
T
+$50.3M
5
UNH icon
UnitedHealth
UNH
+$40.7M

Sector Composition

Rank Sector Weight
1 Healthcare 55.9%
2 Consumer Discretionary 8.93%
3 Technology 8.81%
4 Financials 5.59%
5 Communication Services 4.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRH icon
26
CRH
CRH
$66.8B
$40.4M 1.38%
436,394
-102,500
-19% -$9.86M
UNH icon
27
UnitedHealth
UNH
$370B
$38M 1.3%
75,198
-71,647
-49% -$40.7M
ORCL icon
28
Oracle
ORCL
$423B
$37.7M 1.29%
226,318
-10,776
-5% -$1.91M
IMTX icon
29
Immatics
IMTX
$1.32B
$36M 1.23%
+5,065,277
New +$43.5M
BSX icon
30
Boston Scientific
BSX
$71.5B
$35.5M 1.21%
397,679
+145,990
+58% +$12.9M
GE icon
31
GE Aerospace
GE
$384B
$33.5M 1.14%
200,662
– –
RCKT icon
32
Rocket Pharmaceuticals
RCKT
$394M
$32.3M 1.1%
+2,566,951
New +$38.6M
ERAS icon
33
Erasca
ERAS
$6.39B
$30.9M 1.05%
12,315,004
-1,453,035
-11% -$3.98M
MCD icon
34
McDonald's
MCD
$195B
$30M 1.02%
103,638
– –
VZ icon
35
Verizon
VZ
$196B
$29.5M 1.01%
738,414
-20,260
-3% -$855K
TGTX icon
36
CALL
TG Therapeutics
TGTX
$7.62B
$29.5M 1.01%
+980,000
New +$28.1M
BA icon
37
Boeing
BA
$185B
$27.5M 0.94%
+155,197
New +$24.4M
CZR icon
38
Caesars Entertainment
CZR
$6.14B
$25.8M 0.88%
+772,412
New +$30.6M
APLS
39
DELISTED
Apellis Pharmaceuticals
APLS
$25.3M 0.86%
+793,187
New +$23.9M
DDOG icon
40
Datadog
DDOG
$83.3B
$25.2M 0.86%
+176,450
New +$24.2M
CTNM
41
Contineum Therapeutics
CTNM
$566M
$25.2M 0.86%
1,720,000
– –
NVDA icon
42
NVIDIA
NVDA
$5.42T
$24.3M 0.83%
+180,756
New +$24.9M
PROK icon
43
ProKidney
PROK
$337M
$20.9M 0.71%
12,341,266
– –
ABEO icon
44
Abeona Therapeutics
ABEO
$413M
$20.5M 0.7%
3,685,503
– –
JNJ icon
45
Johnson & Johnson
JNJ
$625B
$20.2M 0.69%
139,986
+1,539
+1% +$238K
UAL icon
46
United Airlines
UAL
$42.1B
$19.5M 0.66%
+200,650
New +$17M
BIIB icon
47
Biogen
BIIB
$30.7B
$17.7M 0.6%
115,436
+85,490
+285% +$14.4M
DPZ icon
48
Domino's
DPZ
$11.6B
$16.1M 0.55%
+38,340
New +$16.8M
FULC icon
49
Fulcrum Therapeutics
FULC
$297M
$15.7M 0.53%
3,338,466
+2,155,675
+182% +$7.95M
IFRX icon
50
InflaRx
IFRX
$271M
$14.2M 0.48%
5,733,910
– –
1
2
3 4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Suvretta Capital Management held 115 positions worth $2.93B, down 6.1% from $3.13B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Suvretta Capital Management's Q4 2024 filing shows 17 new, 19 increased, 24 reduced and 19 closed positions. Its largest new stake was Legend Biotech: 3,496,234 shares worth $114M. The largest sale was Apple, an estimated $78.3M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 53% a quarter earlier, followed by Consumer Discretionary and Technology.

  • Suvretta Capital Management's largest Q4 2024 buy was Legend Biotech: 3,496,234 shares worth $114M.
  • Suvretta Capital Management added most to Coca-Cola in Q4 2024, an estimated $35.8M increase.
  • Suvretta Capital Management's biggest Q4 2024 reduction was UnitedHealth, cutting an estimated $40.7M.
  • Suvretta Capital Management fully exited Apple in Q4 2024, selling an estimated $78.3M.
  • Suvretta Capital Management's ten largest holdings make up 44% of its $2.93B portfolio in Q4 2024.
  • Suvretta Capital Management opened 17 new positions and closed 19 in Q4 2024.
  • Suvretta Capital Management's portfolio value fell 6.1% quarter-over-quarter to $2.93B.

Based on Suvretta Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.